Detail akcie Longeveron Rg-A online

Business Summary: Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Longeveron Inc revenues decreased 53% to $834K. Net loss applicable to common stockholders decreased 16% to $17.3M. Revenues reflect Contract manufacturing segment decrease of 87% to $55K, Clinical trial revenue segment decrease of 36% to $651K. Lower net loss reflects Other (expense) income, net increase of 80% to $628K (income).